Association between CMR‐derived hepatic T1‐time, tricuspid regurgitation and survival
European Journal of Clinical Investigation · 2026-01 · 56 (1)
DOI: 10.1111/eci.70106 ↗Abstract
Abstract Background Cardiac magnetic resonance (CMR) derived hepatic T1‐time is associated with outcome. However, the interplay between tricuspid regurgitation (TR), which can cause congestive hepatopathy and liver T1‐time is unclear. Methods We measured hepatic T1‐time in CMR all‐comers, who underwent echocardiography within 3 weeks of CMR. Kaplan–Meier estimates and Cox regression models were used to investigate the association between hepatic T1‐time, TR severity and a composite endpoint of heart failure hospitalisation and all‐cause death. Results 1029 participants (67 ± 17 y/o, 44% female) had a mean hepatic T1‐time of 605 ± 79 ms. Overall, 41% (417) presented with non/trace, 38% (391) with mild, 13% (135) with moderate and 8% (85) with severe/massive/torrential TR. Liver T1‐time was significantly associated with TR severity (no/trace: 586 ± 72 ms; mild: 601 ± 74 ms; moderate: 634 ± 84 ms; severe/massive/torrential: 665 ± 83 ms; β = 25.4 ms, [95% CI:19.7–31.2, p < .001]). After adjustment for serum NT‐proBNP and right ventricular function in a linear regression model, TR severity remained significantly associated with hepatic T1‐time ( p < .001). During follow‐up (mean 53 ± 36 months) 326 (32%) events occurred. Hepatic T1‐time (adj.HR 1.69 [95% CI: 1.49–1.92] per 100 ms increase, p < .001) and TR (adj.HR 1.66 [95% CI: 1.49–1.84], p < .001) were both associated with outcome. Even after adjustment for serum NT‐proBNP, cardiac structure and function, age, sex and TR severity, hepatic T1‐time remained significantly associated with event‐free survival (adj.HR 1.42 [95% CI: 1.20–1.68] per 100 ms increase, p < .001). Conclusion TR exerts a notable influence on hepatic T1‐time. Nevertheless, after adjustment for serum NTproBNP, cardiac function and TR severity, hepatic T1‐time still independently predicts outcomes. This underscores the importance of hepatic T1‐time both as a marker of TR and prognosis.
EUVIMED